http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 07:00:57 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html <p>Compugen Ltd. (Nasdaq: CGEN) presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, Denmark, on June 18.</p><p>The poster, presented by Dr. Oladapo Yeku of Massachusetts General Hospital in Boston, covered the randomized trial evaluating COM701 as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921.</p><p>COM701 is an anti-PVRIG antibody that Compugen describes as a potential first-in-class therapy. It has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with results showing signs of anti-tumor activity and a tolerability profile that http://www.streetinsider.com/Corporate+News/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html Thu, 18 Jun 2026 07:00:57 -0400 CGEN http://www.streetinsider.com/FDA/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html <p>Compugen Ltd. (Nasdaq: CGEN) presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, Denmark, on June 18.</p><p>The poster, presented by Dr. Oladapo Yeku of Massachusetts General Hospital in Boston, covered the randomized trial evaluating COM701 as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921.</p><p>COM701 is an anti-PVRIG antibody that Compugen describes as a potential first-in-class therapy. It has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with results showing signs of anti-tumor activity and a tolerability profile that http://www.streetinsider.com/FDA/Compugen+presents+COM701+ovarian+cancer+trial+poster+at+ESMO/26662668.html Thu, 18 Jun 2026 07:00:57 -0400 CGEN http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/Press+Releases/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://cgen.com/overview/default.aspx" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p>"We believe there is a strong biologic and clinical rationale for the MAIA-ovarian trial in relapsed platinum-sensitive ovarian cancer, where no standard of care for this maintenance setting http://www.streetinsider.com/PRNewswire/Compugen+Presents+a+Trial-in-Progress+Poster+on+the+MAIA-ovarian+Adaptive+Platform+Trial+at+ESMO+Gynaecological+Cancers+Congress/26662623.html Thu, 18 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Corporate+News/Compugen+to+present+ovarian+cancer+trial+data+at+ESMO+congress/26632439.html <p>Compugen Ltd. (NASDAQ: CGEN) will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study at the ESMO Gynaecological Cancers Congress 2026, according to a company statement.</p><p>The poster presentation will take place June 18, 2026, from 12:45 to 13:30 CEST in Copenhagen, Denmark. Dr. Oladapo Yeku from Massachusetts General Hospital in Boston will present the data.</p><p>The MAIA-ovarian study evaluates COM701, an anti-PVRIG antibody, as maintenance treatment in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921 and represents an adaptive platform clinical trial design.</p><p>COM701 is being developed as a potential treatment for solid tumors and has been http://www.streetinsider.com/Corporate+News/Compugen+to+present+ovarian+cancer+trial+data+at+ESMO+congress/26632439.html Thu, 11 Jun 2026 07:00:43 -0400 CGEN http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/Press+Releases/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365 http://www.streetinsider.com/PRNewswire/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the <span>ESMO Gynaecological Cancers Congress</span> 2026, taking place from <chron>June 17 to June 19, 2026</chron>, in <location value="LU/dk..cophgn" idsrc="xmltag.org" >Copenhagen, Denmark</location>.</p> <p><b>Poster details: </b></p><p><b>Title:</b> MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed http://www.streetinsider.com/PRNewswire/Compugen+to+Present+Phase+1+MAIA-Ovarian+Trial-in-Progress+Poster+at+ESMO+Gynaecological+Cancers+Congress+2026/26632405.html Thu, 11 Jun 2026 07:00:00 -0400 A.40221050 CGEN CGEN CW9 CW9 O.00653212 O.20042365